SlideShare ist ein Scribd-Unternehmen logo
1 von 14
Dataset : PharmaTrac MAT JUN 2017
PharmaTrac Overview
JUN 17
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
INDUSTRY DYNAMICS: Market at 7.5% in June-17 the growth has held steady
in run up to GST implementation….
7084
7149
7078
7595
7543
8063
7294
7539
7620
7533
7450
7624
8337
8016
8158
8549
8544
8874
8900
8263
8606
8350
8489
8265
8828
8790
8801
9508
10031
10096
9690
9478
9247
9129
9047
9081
9551
9416
9463
17.7
12.1
15.3
12.6
13.3
10.1
22.0
9.6
12.9
10.9
13.9
8.4
5.9
9.7
7.9
11.2
17.4
13.8
8.9
14.7
7.5
9.3
6.6
9.9
8.2
7.1 7.5
0.0
5.0
10.0
15.0
20.0
25.0
30.0
0
2000
4000
6000
8000
10000
12000
APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR
Indian Pharma Market Trends - 2014-2018
2014-2015 2015-2016 2016-2017 2017-2018 GR % 2015-2016 GR % 2016-2017 GR % 2017-2018
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
QOQ DYNAMICS: Q2 - 17 growth at 7.6%......... Growth holding steady in
the pre GST implementation period. Chronic port folio driven growth
Q 1 14 Q2 14 Q3 14 Q4 14 Q 1 15 Q 2 15 Q 3 15 Q 4 15 Q 1 16 Q 2 16 Q 3 16 Q 4 16 Q 1 17 Q 2 17
INCRE 1344 1929 2769 2208 3205 3201 2767 3316 2497 1907 3668 2647 2154 2012
19402
21310
23200
22453 22607
24512
25967 25769 25104
26418
29635
28415
27258 28431
7.4
10.0
13.6
10.9
16.5
15.0
11.9
14.8
11.0
7.8
14.1
10.3
8.6
7.6
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
0
5000
10000
15000
20000
25000
30000
35000
VALUE GR
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
7 Corporates in double digit growths for MAT. Glaxo showing a positive MAT
growth after struggling for over a year. Lupin and Zydus and Macleods showing
higher quarterly growths
9584
6883
5051 4637
3625 3673 3726
3340
2978
3081
142
133
257
340
555
250
56
75 254 42
11.3
10.0
6.9
16.8
9.1
10.6
12.7
2.3
11.2
10.5
7.8
7.2
2.6
17.5
10.2
0.0
13.4
8.6
11.2
2.9
0
2
4
6
8
10
12
14
16
18
20
0
2000
4000
6000
8000
10000
12000
SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS
AV BV GR RUN-QTR GR JUN 17
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
ACUTE/CHRONIC SPLIT: Chronic and Sub chronic categories driving growth
GR
IPM SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS
11.2 15.6 14.0 14.4 14.0 12.2 12.6 3.3 6.2 21.8 22.6
12.0 15.0 10.5 11.7 11.0 16.7 15.7 17.0 2.5 3.7 6.0
8.5 5.9 7.4 0.9 21.7 5.0 9.1 11.8 1.0 11.9 10.5
48
39 38
44
51 55
64
32
65
48
25
32 47
41
43 31 25 11
51
13
30
53
20
14
20
13
18 19
25
18 22 21 22
IPM SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS
ACUTE CHRONIC SUB CHRONIC
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
RANK SPLIT: Top 10 Contribute 42.75% to the IPM. Smaller and tail-
ender companies growing slower than the market
Jun-16 Jun-17
MAT VAL MS GR CORPORATE MAT VAL MS GR
103258 100.00 11.3 IPM 113739 100.00 10.1
44146 42.75 11.1 TOP 10 48682 42.80 10.3
28385 27.49 11.4 11-25 31465 27.66 10.9
14294 13.84 16.0 26 - 50 15798 13.89 10.5
10164 9.84 7.0 51 - 100 11135 9.79 9.5
6269 6.07 9.3 100 + 6660 5.86 6.2
42.75
27.49
13.84
9.84 6.07
JUN-16
TOP 10 11 - 25 26 - 50 51 - 100 100 +
42.80
27.66
13.89
9.79 5.86
JUN-17
TOP 10 11 - 25 26 - 50 51 - 100 100 +
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
INDIAN/MNC SPLIT: Indian Companies dominate & are growing above the
Market on MAT basis. However for the Month June-17 MNC collectively
growing better than Indian companies
GR VAL : 10.8 GR VAL : 7.7IPM GR VAL : 10.1
0200040006000800010000
SUN*,
9726
CIPLA,
5308
ZYDUS*,
4977
MANKIN
D, 4180
ALKEM*,
3924
79.08
20.92
INDIAN MNC
0 2000 4000 6000 8000
ABBOTT*,
7015
GSK, 3415
PFIZER*,
2846
SANOFI
INDIA,
2534
NOVARTIS,
1075
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
* Abbott + Abbott HC + Novo; Alkem + Indchemie + Cachet; Pfizer + Wyeth; Zydus + Biochem; Micro + Bal
ZONAL SPLIT: South dominates rest of the zones growing slower
than the IPM
26.8%
25.8%
20.1%
23.5%
JUN-17
20.1%
23.5%
20.2% 26.5%
22.4% 25.8%
20.2% 26.7%
22.1% 25.6%
SOUTH ZONE
NORTH ZONE
WEST ZONE
EAST ZONE
ZONE
JUN-16
MAT VAL JUN 17
ZONE MAT VAL MS MS (G / L) GR INCRE VAL
IPM 113739 100.00% 0.00% 10.1 10480
SOUTH ZONE 30421 26.75% 0.21% 11.0 3024
NORTH ZONE 29088 25.57% -0.24% 9.1 2429
WEST ZONE 25181 22.14% -0.24% 9.0 2074
EAST ZONE 22959 20.19% -0.04% 9.9 2076
ALL INDIA ONLY 6089 5.35% 0.31% 16.8 877
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
Top 3 Markets constitutes 38.2% of IPM…….Anti-Diabetics adds Maximum
incremental value on MAT basis, followed by Anti-infectives and CVS….
MAT VAL JUN 17 MS
SUPERGROUP SV BV GR INCRE VAL BV % TO SV SV BV
IPM 113739 4273 10.1 10480 3.8 100.00 100.00
ANTI-INFECTIVES 16217 1255 4.6 708 7.7 14.26 29.37
CARDIAC 14025 122 11.4 1433 0.9 12.33 2.84
GASTRO INTESTINAL 13198 464 9.9 1184 3.5 11.60 10.87
ANTI DIABETIC 10148 82 19.2 1637 0.8 8.92 1.91
VITAMINS / MINERALS / NUTRIENTS 9951 278 8.6 786 2.8 8.75 6.51
RESPIRATORY 8478 351 9.4 727 4.1 7.45 8.21
PAIN / ANALGESICS 7832 347 9.8 699 4.4 6.89 8.12
DERMA 6859 209 12.7 772 3.1 6.03 4.90
NEURO / CNS 6847 79 8.4 533 1.2 6.02 1.86
GYNAECOLOGICAL 5926 479 11.1 594 8.1 5.21 11.22
ANTI-NEOPLASTICS 2391 5 7.2 160 0.2 2.10 0.12
VACCINES 2131 117 20.3 360 5.5 1.87 2.74
OPHTHAL / OTOLOGICALS 2085 31 6.4 126 1.5 1.83 0.72
HORMONES 1918 16 9.0 159 0.8 1.69 0.38
BLOOD RELATED 1436 32 14.2 178 2.2 1.26 0.74
UROLOGY 1318 23 11.5 136 1.8 1.16 0.55
OTHERS 1241 48 16.1 172 3.9 1.09 1.12
SEX STIMULANTS / REJUVENATORS 653 230 16.9 94 35.3 0.57 5.39
ANTI MALARIALS 586 91 -1.0 -6.0 15.5 0.52 2.13
STOMATOLOGICALS 499 13 5.5 26 2.6 0.44 0.30
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
Mixtard leads………..6 out of top 20 Anti-diabetic……………Three brands
adding 90Crs or more amongst top 10
RANK Jun-17
Jun-17 G/L BRAND SUBGROUP CORPORATE SV AV BV GR INCRE
0 0 IPM 113739 109466 4273 10.1 10480
1 0 MIXTARD HUMAN PREMIX ABBOTT* 517 511 6 6.1 30
2 1 GLYCOMET GP GLIMEPIRIDE + METFORMIN USV 433 424 9 26.4 90
3 2 SPASMO PROXYVON PLUS DICYCLOMINE + PARACETAMOL + TRAMADOL WOCKHARDT 422 422 1 32.1 103
4 3 GALVUS MET VILDAGLIPTIN + METFORMIN NOVARTIS 362 353 8 24.7 72
5 5 LANTUS GLARGINE SANOFI INDIA 340 336 3 27.1 72
6 6 JANUMET SITAGLIPTIN + METFORMIN MSD* 310 309 1 24.4 61
7 2 LIV 52 HEPATIC PROTECTORS INCLUDING AYURVEDIC HIMALAYA 296 294 2 9.2 25
8 -2 AUGMENTIN AMOXYCILLIN + CLAVULANIC ACID GSK 295 293 1 -2.5 -8
9 15 NOVOMIX BIPHASIC ASPART ABBOTT* 284 283 1 49.7 94
10 1 CLAVAM AMOXYCILLIN + CLAVULANIC ACID ALKEM* 280 242 39 10.4 26
11 -3 MONOCEF CEFTRIAXONE ARISTO 278 215 63 1.4 4
12 9 SYNFLORIX ALL OTHER VACCINES GSK 252 230 22 27.0 54
13 4 PAN PANTOPRAZOLE ALKEM* 251 245 6 19.4 41
14 11 HEPCINAT SOFOSBUVIR NATCO 250 237 14 35.0 65
15 -1 VOLINI DICLOFENAC SUN* 240 223 17 4.4 10
16 4 FORACORT FORMOTERAL + BUDESONIDE CIPLA 231 228 3 15.0 30
17 6 VOVERAN DICLOFENAC NOVARTIS 227 213 14 14.9 29
18 16 DUPHASTON DYDROGESTERONE ABBOTT* 226 222 4 29.2 51
19 -3 BECOSULES VITAMIN B COMPLEX WITH VITAMIN C ONLY PFIZER* 224 216 8 2.2 5
20 -5 ACILOC RANITIDINE CADILA 223 219 4 -2.7 -6
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
69 Brands cross 10 Crs launched……….64 NIs in Itraconazole & more than 100
brands launched in Teneligliptin and combinations segment
Jun-17
BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL
NI BRANDS(LAST 24 MONTHS) 4525 3344
HEXAXIM COMBINATIONS WITH TETANUS COMPONENT SANOFI INDIA Oct-16 112 112
PANDERM NM CLOBETASOL + NEOMYCIN + MICONAZOLE MACLEODS May-16 104 93
HEPCINAT LP SOFOSBUVIR + LEDIPASVIR NATCO Jan-16 99 -72
JARDIANCE EMPAGLIFLOZIN BOEHRINGER INGELHEIM Oct-15 94 72
NATDAC DACLATASVIR NATCO May-16 81 79
VIVITRA TRASTUZUMAB ZYDUS* Jan-16 71 58
IT-MAC ITRACONAZOLE MACLEODS Oct-15 55 44
AXCER TICAGRELOR SUN* Oct-15 55 42
ZITAMET PLUS TENELIGLIPTIN + METFORMIN GLENMARK Oct-15 47 28
INSTA MIFEPRISTONE + MISOPROSTOL MACLEODS Apr-16 40 29
SULISENT CANAGLIFLOZIN USV Oct-15 40 27
ONDERO LINAGLIPTIN LUPIN Nov-15 40 29
DECA DURABOLIN NANDROLONE ZYDUS* Jan-17 34 34
BGR 34 AYURVEDIC AIMIL Oct-15 31 15
ONDERO MET LINAGLIPTIN + METFORMIN LUPIN Mar-16 30 27
TENGLYN TENELIGLIPTIN ZYDUS* Nov-15 29 16
PRIORIX TETRA
COMBINATIONS WITH MEASLES AND / OR
MUMPS (E.G. MMR)
GSK Jul-16 29 29
ZITEN M TENELIGLIPTIN + METFORMIN GLENMARK Oct-15 28 18
AMBRODIL S PLUS LEVOSALBUTAMOL + AMBROXOL ARISTO Aug-16 28 28
CEREBROLYSIN CEREBROPROTEIN HYDROLYSATE SUN* Jul-15 27 5
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
6325 Brands launched in last 24 months…
Jun-17
BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL
NI BRANDS(LAST 24 MONTHS) 4525 3344
CARIPILL CARICA PAPAYA COMBINATIONS MICRO* Jul-15 27 11
NICOTEX PLUS NICOTINE CIPLA Aug-15 24 14
LUPIHEME ELEMENTAL IRON LUPIN Sep-15 21 14
GIBTULIO EMPAGLIFLOZIN LUPIN Sep-16 21 21
DYNAGLIPT TENELIGLIPTIN MANKIND Nov-15 20 14
TENEPRIDE TENELIGLIPTIN MICRO* Nov-15 20 12
DACIHEP DACLATASVIR ZYDUS* Dec-15 20 14
GESTAREST MIFEPRISTONE + MISOPROSTOL MACLEODS Mar-16 17 12
SINAREST NEW PARACETAMOL + PHENYLEPHRINE + CHLORPHENIRAMINE CENTAUR May-16 17 17
LULICAN LULICONAZOLE GLENMARK Jul-16 17 17
OXRA DAPAGLIFLOZIN SUN* Aug-16 17 17
LULIBET LULICONAZOLE INTAS Jul-16 17 17
TENDIA TENELIGLIPTIN KINEDEX Oct-15 17 10
TERBINAFORCE LITE CLOTRIMAZOLE + CLOBETASOL + NEOMYCIN MANKIND Jul-16 16 16
TENDIA M TENELIGLIPTIN + METFORMIN KINEDEX Mar-16 16 14
NOVOGERMINA BACILLUS CLAUSII ALKEM* Apr-16 16 14
RESOF L SOFOSBUVIR + LEDIPASVIR DR. REDDYS Dec-15 15 12
LEDIHEP SOFOSBUVIR + LEDIPASVIR ZYDUS* Dec-15 15 10
TENLIMAC TENELIGLIPTIN MACLEODS Dec-15 14 11
TENIVA TENELIGLIPTIN INTAS Oct-15 14 6
Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs)
Jun-17
BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL
NI BRANDS(LAST 24 MONTHS) 4525 3344
REVITAL H WOMAN GINSENG PRODUCTS SUN* Jan-16 14 8
TRULICITY DULAGLUTIDE ELI LILLY Mar-16 13 12
AZTOLET ATORVASTATIN + CLOPIDOGREL SUN* Aug-15 13 7
LOMOFEN PLUS LOPERAMIDE RPG Apr-16 12 11
SOFAB LP SOFOSBUVIR + LEDIPASVIR SUN* Jan-16 12 5
HEPAGLAN OTHER HEPARINS GLAND May-16 12 11
ROZAGOLD ASPIRIN + ROSUVASTATIN + CLOPIDOGREL SUN* Apr-16 12 11
MACTOTAL OMEGA FATTY ACIDS MACLEODS Dec-15 11 7
MEROFIC PLUS MEROPENEM GUFIC BIOSCIENCE Aug-15 11 8
FIBRISTAL ULIPRISTAL ACETATE AKUMENTIS Nov-15 11 8
ACOGUT ACOTIAMIDE LUPIN Aug-16 11 11
MYCHIRO MYO-INOSITOL + D-CHIROINOSITOL USV Apr-16 11 10
TGLIP TENELIGLIPTIN INTAS Oct-15 11 6
IXAROLA RIVAROXABAN ZYDUS* Oct-15 11 9
ETERNEX T TENELIGLIPTIN ALEMBIC Oct-15 11 6
OSTERI TERIPARATIDE EMCURE* Jul-16 11 11
LOFTAIR GLYCOPYRROLATE + INDACATEROL LUPIN Dec-15 11 7
EASY SIX ALL OTHER VACCINES PANACEA Apr-17 11 11
ENSURE PLUS OTHER NUTRIENTS ABBOTT* Oct-15 11 9
CEASTRA ITRACONAZOLE EMCURE* Sep-16 11 11
6325 Brands launched in last 24 months…
Dataset : PharmaTrac MAT JUN 2017

Weitere ähnliche Inhalte

Ă„hnlich wie Indian Pharma Market - June 2017 Sales Highlights

A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)Md. Mahfizur RAHMAN [Sohag]
 
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)Md. Mahfizur RAHMAN [Sohag]
 
India Market Reflection Report Feb 2015
India Market Reflection Report Feb 2015India Market Reflection Report Feb 2015
India Market Reflection Report Feb 2015QuintilesIMS Asia Pacific
 
08.3 corporate credit analysis
08.3   corporate credit analysis08.3   corporate credit analysis
08.3 corporate credit analysiscrmbasel
 
Tpa Training Module
Tpa Training ModuleTpa Training Module
Tpa Training Modulemyshivin
 
505 b 2 strategy and Rx to otc switch market overview = ishan shukla
505 b 2 strategy and Rx to otc switch market overview = ishan shukla505 b 2 strategy and Rx to otc switch market overview = ishan shukla
505 b 2 strategy and Rx to otc switch market overview = ishan shuklaIshan Shukla
 
Ukrainian Pharmaceutical Market Monthly - Upharmacia - Oct 2017
Ukrainian Pharmaceutical Market Monthly - Upharmacia - Oct 2017Ukrainian Pharmaceutical Market Monthly - Upharmacia - Oct 2017
Ukrainian Pharmaceutical Market Monthly - Upharmacia - Oct 2017Eirhub
 

Ă„hnlich wie Indian Pharma Market - June 2017 Sales Highlights (10)

A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
 
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
A presentation on ims 1st , 2016.pptx, (Ophthalmic Bangladesh)
 
India Market Reflection Report Feb 2015
India Market Reflection Report Feb 2015India Market Reflection Report Feb 2015
India Market Reflection Report Feb 2015
 
Equity Daily report 19 july
Equity Daily report 19 julyEquity Daily report 19 july
Equity Daily report 19 july
 
Etizola brand plan
Etizola brand planEtizola brand plan
Etizola brand plan
 
08.3 corporate credit analysis
08.3   corporate credit analysis08.3   corporate credit analysis
08.3 corporate credit analysis
 
Tpa Training Module
Tpa Training ModuleTpa Training Module
Tpa Training Module
 
505 b 2 strategy and Rx to otc switch market overview = ishan shukla
505 b 2 strategy and Rx to otc switch market overview = ishan shukla505 b 2 strategy and Rx to otc switch market overview = ishan shukla
505 b 2 strategy and Rx to otc switch market overview = ishan shukla
 
Ukrainian Pharmaceutical Market Monthly - Upharmacia - Oct 2017
Ukrainian Pharmaceutical Market Monthly - Upharmacia - Oct 2017Ukrainian Pharmaceutical Market Monthly - Upharmacia - Oct 2017
Ukrainian Pharmaceutical Market Monthly - Upharmacia - Oct 2017
 
Indices 15 jul2014042809
Indices 15 jul2014042809Indices 15 jul2014042809
Indices 15 jul2014042809
 

Mehr von Anup Soans

An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...Anup Soans
 
Key Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way ForwardKey Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way ForwardAnup Soans
 
Trends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and SpendingTrends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and SpendingAnup Soans
 
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27thMedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27thAnup Soans
 
Key Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAMKey Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAMAnup Soans
 
MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021Anup Soans
 
How can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand PatientsHow can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand PatientsAnup Soans
 
Why Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop TalentWhy Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop TalentAnup Soans
 
Digital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification ProgramDigital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification ProgramAnup Soans
 
Digital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification ProgramDigital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification ProgramAnup Soans
 
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family AffairsCOVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family AffairsAnup Soans
 
Architecture To Develop Pharma Business Leaders For Today and Tomorrow
Architecture To Develop Pharma Business Leaders  For Today and Tomorrow  Architecture To Develop Pharma Business Leaders  For Today and Tomorrow
Architecture To Develop Pharma Business Leaders For Today and Tomorrow Anup Soans
 
What is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research ProjectWhat is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research ProjectAnup Soans
 
Digital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification ProgramDigital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification ProgramAnup Soans
 
Telemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian DoctorsTelemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian DoctorsAnup Soans
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalAnup Soans
 
Indian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View PollIndian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View PollAnup Soans
 
Healthcare's Future will be Patient Experience
Healthcare's Future will be Patient ExperienceHealthcare's Future will be Patient Experience
Healthcare's Future will be Patient ExperienceAnup Soans
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Anup Soans
 
MedicinMan December 2018 Issue
MedicinMan December 2018 IssueMedicinMan December 2018 Issue
MedicinMan December 2018 IssueAnup Soans
 

Mehr von Anup Soans (20)

An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
An Infectious Disease Specialist, Dr Mandar Kubal Speaks to Pharma on How it ...
 
Key Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way ForwardKey Challenges Facing Pharma Industry and the Way Forward
Key Challenges Facing Pharma Industry and the Way Forward
 
Trends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and SpendingTrends in Pharma Marketing - Focus and Spending
Trends in Pharma Marketing - Focus and Spending
 
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27thMedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
MedicinMan CEO Roundtable 2021 is here... Saturday, Feb 27th
 
Key Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAMKey Account Management - Time for India Pharma to Adopt KAM
Key Account Management - Time for India Pharma to Adopt KAM
 
MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021MedicinMan Report on Digital Readiness of Indian Pharma 2021
MedicinMan Report on Digital Readiness of Indian Pharma 2021
 
How can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand PatientsHow can Pharma Use Digital to Engage Doctors and Understand Patients
How can Pharma Use Digital to Engage Doctors and Understand Patients
 
Why Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop TalentWhy Indian Pharma Needs to Enable Managers to Develop Talent
Why Indian Pharma Needs to Enable Managers to Develop Talent
 
Digital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification ProgramDigital Excellence Pharma Academy Certification Program
Digital Excellence Pharma Academy Certification Program
 
Digital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification ProgramDigital Excellent Pharma Academy Certification Program
Digital Excellent Pharma Academy Certification Program
 
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family AffairsCOVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
COVID-19 Vaccine Roll Out Plan by Ministry of Health and Family Affairs
 
Architecture To Develop Pharma Business Leaders For Today and Tomorrow
Architecture To Develop Pharma Business Leaders  For Today and Tomorrow  Architecture To Develop Pharma Business Leaders  For Today and Tomorrow
Architecture To Develop Pharma Business Leaders For Today and Tomorrow
 
What is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research ProjectWhat is Indian Pharma Thinking about Digital? A Research Project
What is Indian Pharma Thinking about Digital? A Research Project
 
Digital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification ProgramDigital Excellence Pharma Academy - Webinar & Online Certification Program
Digital Excellence Pharma Academy - Webinar & Online Certification Program
 
Telemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian DoctorsTelemedicine Guidelines for Indian Doctors
Telemedicine Guidelines for Indian Doctors
 
The Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit GhoshalThe Mankind Pharma Story by Dr. Sumit Ghoshal
The Mankind Pharma Story by Dr. Sumit Ghoshal
 
Indian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View PollIndian Pharma and Retail Pharmacies - Sales View Poll
Indian Pharma and Retail Pharmacies - Sales View Poll
 
Healthcare's Future will be Patient Experience
Healthcare's Future will be Patient ExperienceHealthcare's Future will be Patient Experience
Healthcare's Future will be Patient Experience
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan
 
MedicinMan December 2018 Issue
MedicinMan December 2018 IssueMedicinMan December 2018 Issue
MedicinMan December 2018 Issue
 

KĂĽrzlich hochgeladen

Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingArunagarwal328757
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptkedirjemalharun
 

KĂĽrzlich hochgeladen (20)

Pharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, PricingPharmaceutical Marketting: Unit-5, Pricing
Pharmaceutical Marketting: Unit-5, Pricing
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Apiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.pptApiculture Chapter 1. Introduction 2.ppt
Apiculture Chapter 1. Introduction 2.ppt
 

Indian Pharma Market - June 2017 Sales Highlights

  • 1. Dataset : PharmaTrac MAT JUN 2017 PharmaTrac Overview JUN 17
  • 2. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) INDUSTRY DYNAMICS: Market at 7.5% in June-17 the growth has held steady in run up to GST implementation…. 7084 7149 7078 7595 7543 8063 7294 7539 7620 7533 7450 7624 8337 8016 8158 8549 8544 8874 8900 8263 8606 8350 8489 8265 8828 8790 8801 9508 10031 10096 9690 9478 9247 9129 9047 9081 9551 9416 9463 17.7 12.1 15.3 12.6 13.3 10.1 22.0 9.6 12.9 10.9 13.9 8.4 5.9 9.7 7.9 11.2 17.4 13.8 8.9 14.7 7.5 9.3 6.6 9.9 8.2 7.1 7.5 0.0 5.0 10.0 15.0 20.0 25.0 30.0 0 2000 4000 6000 8000 10000 12000 APR MAY JUN JUL AUG SEP OCT NOV DEC JAN FEB MAR Indian Pharma Market Trends - 2014-2018 2014-2015 2015-2016 2016-2017 2017-2018 GR % 2015-2016 GR % 2016-2017 GR % 2017-2018
  • 3. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) QOQ DYNAMICS: Q2 - 17 growth at 7.6%......... Growth holding steady in the pre GST implementation period. Chronic port folio driven growth Q 1 14 Q2 14 Q3 14 Q4 14 Q 1 15 Q 2 15 Q 3 15 Q 4 15 Q 1 16 Q 2 16 Q 3 16 Q 4 16 Q 1 17 Q 2 17 INCRE 1344 1929 2769 2208 3205 3201 2767 3316 2497 1907 3668 2647 2154 2012 19402 21310 23200 22453 22607 24512 25967 25769 25104 26418 29635 28415 27258 28431 7.4 10.0 13.6 10.9 16.5 15.0 11.9 14.8 11.0 7.8 14.1 10.3 8.6 7.6 0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 0 5000 10000 15000 20000 25000 30000 35000 VALUE GR
  • 4. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) 7 Corporates in double digit growths for MAT. Glaxo showing a positive MAT growth after struggling for over a year. Lupin and Zydus and Macleods showing higher quarterly growths 9584 6883 5051 4637 3625 3673 3726 3340 2978 3081 142 133 257 340 555 250 56 75 254 42 11.3 10.0 6.9 16.8 9.1 10.6 12.7 2.3 11.2 10.5 7.8 7.2 2.6 17.5 10.2 0.0 13.4 8.6 11.2 2.9 0 2 4 6 8 10 12 14 16 18 20 0 2000 4000 6000 8000 10000 12000 SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS AV BV GR RUN-QTR GR JUN 17
  • 5. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) ACUTE/CHRONIC SPLIT: Chronic and Sub chronic categories driving growth GR IPM SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS 11.2 15.6 14.0 14.4 14.0 12.2 12.6 3.3 6.2 21.8 22.6 12.0 15.0 10.5 11.7 11.0 16.7 15.7 17.0 2.5 3.7 6.0 8.5 5.9 7.4 0.9 21.7 5.0 9.1 11.8 1.0 11.9 10.5 48 39 38 44 51 55 64 32 65 48 25 32 47 41 43 31 25 11 51 13 30 53 20 14 20 13 18 19 25 18 22 21 22 IPM SUN* ABBOTT* CIPLA ZYDUS* MANKIND ALKEM* LUPIN GSK MACLEODS INTAS ACUTE CHRONIC SUB CHRONIC
  • 6. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) RANK SPLIT: Top 10 Contribute 42.75% to the IPM. Smaller and tail- ender companies growing slower than the market Jun-16 Jun-17 MAT VAL MS GR CORPORATE MAT VAL MS GR 103258 100.00 11.3 IPM 113739 100.00 10.1 44146 42.75 11.1 TOP 10 48682 42.80 10.3 28385 27.49 11.4 11-25 31465 27.66 10.9 14294 13.84 16.0 26 - 50 15798 13.89 10.5 10164 9.84 7.0 51 - 100 11135 9.79 9.5 6269 6.07 9.3 100 + 6660 5.86 6.2 42.75 27.49 13.84 9.84 6.07 JUN-16 TOP 10 11 - 25 26 - 50 51 - 100 100 + 42.80 27.66 13.89 9.79 5.86 JUN-17 TOP 10 11 - 25 26 - 50 51 - 100 100 +
  • 7. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) INDIAN/MNC SPLIT: Indian Companies dominate & are growing above the Market on MAT basis. However for the Month June-17 MNC collectively growing better than Indian companies GR VAL : 10.8 GR VAL : 7.7IPM GR VAL : 10.1 0200040006000800010000 SUN*, 9726 CIPLA, 5308 ZYDUS*, 4977 MANKIN D, 4180 ALKEM*, 3924 79.08 20.92 INDIAN MNC 0 2000 4000 6000 8000 ABBOTT*, 7015 GSK, 3415 PFIZER*, 2846 SANOFI INDIA, 2534 NOVARTIS, 1075
  • 8. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) * Abbott + Abbott HC + Novo; Alkem + Indchemie + Cachet; Pfizer + Wyeth; Zydus + Biochem; Micro + Bal ZONAL SPLIT: South dominates rest of the zones growing slower than the IPM 26.8% 25.8% 20.1% 23.5% JUN-17 20.1% 23.5% 20.2% 26.5% 22.4% 25.8% 20.2% 26.7% 22.1% 25.6% SOUTH ZONE NORTH ZONE WEST ZONE EAST ZONE ZONE JUN-16 MAT VAL JUN 17 ZONE MAT VAL MS MS (G / L) GR INCRE VAL IPM 113739 100.00% 0.00% 10.1 10480 SOUTH ZONE 30421 26.75% 0.21% 11.0 3024 NORTH ZONE 29088 25.57% -0.24% 9.1 2429 WEST ZONE 25181 22.14% -0.24% 9.0 2074 EAST ZONE 22959 20.19% -0.04% 9.9 2076 ALL INDIA ONLY 6089 5.35% 0.31% 16.8 877
  • 9. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) Top 3 Markets constitutes 38.2% of IPM…….Anti-Diabetics adds Maximum incremental value on MAT basis, followed by Anti-infectives and CVS…. MAT VAL JUN 17 MS SUPERGROUP SV BV GR INCRE VAL BV % TO SV SV BV IPM 113739 4273 10.1 10480 3.8 100.00 100.00 ANTI-INFECTIVES 16217 1255 4.6 708 7.7 14.26 29.37 CARDIAC 14025 122 11.4 1433 0.9 12.33 2.84 GASTRO INTESTINAL 13198 464 9.9 1184 3.5 11.60 10.87 ANTI DIABETIC 10148 82 19.2 1637 0.8 8.92 1.91 VITAMINS / MINERALS / NUTRIENTS 9951 278 8.6 786 2.8 8.75 6.51 RESPIRATORY 8478 351 9.4 727 4.1 7.45 8.21 PAIN / ANALGESICS 7832 347 9.8 699 4.4 6.89 8.12 DERMA 6859 209 12.7 772 3.1 6.03 4.90 NEURO / CNS 6847 79 8.4 533 1.2 6.02 1.86 GYNAECOLOGICAL 5926 479 11.1 594 8.1 5.21 11.22 ANTI-NEOPLASTICS 2391 5 7.2 160 0.2 2.10 0.12 VACCINES 2131 117 20.3 360 5.5 1.87 2.74 OPHTHAL / OTOLOGICALS 2085 31 6.4 126 1.5 1.83 0.72 HORMONES 1918 16 9.0 159 0.8 1.69 0.38 BLOOD RELATED 1436 32 14.2 178 2.2 1.26 0.74 UROLOGY 1318 23 11.5 136 1.8 1.16 0.55 OTHERS 1241 48 16.1 172 3.9 1.09 1.12 SEX STIMULANTS / REJUVENATORS 653 230 16.9 94 35.3 0.57 5.39 ANTI MALARIALS 586 91 -1.0 -6.0 15.5 0.52 2.13 STOMATOLOGICALS 499 13 5.5 26 2.6 0.44 0.30
  • 10. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) Mixtard leads………..6 out of top 20 Anti-diabetic……………Three brands adding 90Crs or more amongst top 10 RANK Jun-17 Jun-17 G/L BRAND SUBGROUP CORPORATE SV AV BV GR INCRE 0 0 IPM 113739 109466 4273 10.1 10480 1 0 MIXTARD HUMAN PREMIX ABBOTT* 517 511 6 6.1 30 2 1 GLYCOMET GP GLIMEPIRIDE + METFORMIN USV 433 424 9 26.4 90 3 2 SPASMO PROXYVON PLUS DICYCLOMINE + PARACETAMOL + TRAMADOL WOCKHARDT 422 422 1 32.1 103 4 3 GALVUS MET VILDAGLIPTIN + METFORMIN NOVARTIS 362 353 8 24.7 72 5 5 LANTUS GLARGINE SANOFI INDIA 340 336 3 27.1 72 6 6 JANUMET SITAGLIPTIN + METFORMIN MSD* 310 309 1 24.4 61 7 2 LIV 52 HEPATIC PROTECTORS INCLUDING AYURVEDIC HIMALAYA 296 294 2 9.2 25 8 -2 AUGMENTIN AMOXYCILLIN + CLAVULANIC ACID GSK 295 293 1 -2.5 -8 9 15 NOVOMIX BIPHASIC ASPART ABBOTT* 284 283 1 49.7 94 10 1 CLAVAM AMOXYCILLIN + CLAVULANIC ACID ALKEM* 280 242 39 10.4 26 11 -3 MONOCEF CEFTRIAXONE ARISTO 278 215 63 1.4 4 12 9 SYNFLORIX ALL OTHER VACCINES GSK 252 230 22 27.0 54 13 4 PAN PANTOPRAZOLE ALKEM* 251 245 6 19.4 41 14 11 HEPCINAT SOFOSBUVIR NATCO 250 237 14 35.0 65 15 -1 VOLINI DICLOFENAC SUN* 240 223 17 4.4 10 16 4 FORACORT FORMOTERAL + BUDESONIDE CIPLA 231 228 3 15.0 30 17 6 VOVERAN DICLOFENAC NOVARTIS 227 213 14 14.9 29 18 16 DUPHASTON DYDROGESTERONE ABBOTT* 226 222 4 29.2 51 19 -3 BECOSULES VITAMIN B COMPLEX WITH VITAMIN C ONLY PFIZER* 224 216 8 2.2 5 20 -5 ACILOC RANITIDINE CADILA 223 219 4 -2.7 -6
  • 11. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) 69 Brands cross 10 Crs launched……….64 NIs in Itraconazole & more than 100 brands launched in Teneligliptin and combinations segment Jun-17 BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL NI BRANDS(LAST 24 MONTHS) 4525 3344 HEXAXIM COMBINATIONS WITH TETANUS COMPONENT SANOFI INDIA Oct-16 112 112 PANDERM NM CLOBETASOL + NEOMYCIN + MICONAZOLE MACLEODS May-16 104 93 HEPCINAT LP SOFOSBUVIR + LEDIPASVIR NATCO Jan-16 99 -72 JARDIANCE EMPAGLIFLOZIN BOEHRINGER INGELHEIM Oct-15 94 72 NATDAC DACLATASVIR NATCO May-16 81 79 VIVITRA TRASTUZUMAB ZYDUS* Jan-16 71 58 IT-MAC ITRACONAZOLE MACLEODS Oct-15 55 44 AXCER TICAGRELOR SUN* Oct-15 55 42 ZITAMET PLUS TENELIGLIPTIN + METFORMIN GLENMARK Oct-15 47 28 INSTA MIFEPRISTONE + MISOPROSTOL MACLEODS Apr-16 40 29 SULISENT CANAGLIFLOZIN USV Oct-15 40 27 ONDERO LINAGLIPTIN LUPIN Nov-15 40 29 DECA DURABOLIN NANDROLONE ZYDUS* Jan-17 34 34 BGR 34 AYURVEDIC AIMIL Oct-15 31 15 ONDERO MET LINAGLIPTIN + METFORMIN LUPIN Mar-16 30 27 TENGLYN TENELIGLIPTIN ZYDUS* Nov-15 29 16 PRIORIX TETRA COMBINATIONS WITH MEASLES AND / OR MUMPS (E.G. MMR) GSK Jul-16 29 29 ZITEN M TENELIGLIPTIN + METFORMIN GLENMARK Oct-15 28 18 AMBRODIL S PLUS LEVOSALBUTAMOL + AMBROXOL ARISTO Aug-16 28 28 CEREBROLYSIN CEREBROPROTEIN HYDROLYSATE SUN* Jul-15 27 5
  • 12. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) 6325 Brands launched in last 24 months… Jun-17 BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL NI BRANDS(LAST 24 MONTHS) 4525 3344 CARIPILL CARICA PAPAYA COMBINATIONS MICRO* Jul-15 27 11 NICOTEX PLUS NICOTINE CIPLA Aug-15 24 14 LUPIHEME ELEMENTAL IRON LUPIN Sep-15 21 14 GIBTULIO EMPAGLIFLOZIN LUPIN Sep-16 21 21 DYNAGLIPT TENELIGLIPTIN MANKIND Nov-15 20 14 TENEPRIDE TENELIGLIPTIN MICRO* Nov-15 20 12 DACIHEP DACLATASVIR ZYDUS* Dec-15 20 14 GESTAREST MIFEPRISTONE + MISOPROSTOL MACLEODS Mar-16 17 12 SINAREST NEW PARACETAMOL + PHENYLEPHRINE + CHLORPHENIRAMINE CENTAUR May-16 17 17 LULICAN LULICONAZOLE GLENMARK Jul-16 17 17 OXRA DAPAGLIFLOZIN SUN* Aug-16 17 17 LULIBET LULICONAZOLE INTAS Jul-16 17 17 TENDIA TENELIGLIPTIN KINEDEX Oct-15 17 10 TERBINAFORCE LITE CLOTRIMAZOLE + CLOBETASOL + NEOMYCIN MANKIND Jul-16 16 16 TENDIA M TENELIGLIPTIN + METFORMIN KINEDEX Mar-16 16 14 NOVOGERMINA BACILLUS CLAUSII ALKEM* Apr-16 16 14 RESOF L SOFOSBUVIR + LEDIPASVIR DR. REDDYS Dec-15 15 12 LEDIHEP SOFOSBUVIR + LEDIPASVIR ZYDUS* Dec-15 15 10 TENLIMAC TENELIGLIPTIN MACLEODS Dec-15 14 11 TENIVA TENELIGLIPTIN INTAS Oct-15 14 6
  • 13. Dataset : PharmaTrac MAT JUN 2017 (Val in Crs)(Val in Crs) Jun-17 BRAND SUBGROUP COMPANY LD MAT VAL INCRE VAL NI BRANDS(LAST 24 MONTHS) 4525 3344 REVITAL H WOMAN GINSENG PRODUCTS SUN* Jan-16 14 8 TRULICITY DULAGLUTIDE ELI LILLY Mar-16 13 12 AZTOLET ATORVASTATIN + CLOPIDOGREL SUN* Aug-15 13 7 LOMOFEN PLUS LOPERAMIDE RPG Apr-16 12 11 SOFAB LP SOFOSBUVIR + LEDIPASVIR SUN* Jan-16 12 5 HEPAGLAN OTHER HEPARINS GLAND May-16 12 11 ROZAGOLD ASPIRIN + ROSUVASTATIN + CLOPIDOGREL SUN* Apr-16 12 11 MACTOTAL OMEGA FATTY ACIDS MACLEODS Dec-15 11 7 MEROFIC PLUS MEROPENEM GUFIC BIOSCIENCE Aug-15 11 8 FIBRISTAL ULIPRISTAL ACETATE AKUMENTIS Nov-15 11 8 ACOGUT ACOTIAMIDE LUPIN Aug-16 11 11 MYCHIRO MYO-INOSITOL + D-CHIROINOSITOL USV Apr-16 11 10 TGLIP TENELIGLIPTIN INTAS Oct-15 11 6 IXAROLA RIVAROXABAN ZYDUS* Oct-15 11 9 ETERNEX T TENELIGLIPTIN ALEMBIC Oct-15 11 6 OSTERI TERIPARATIDE EMCURE* Jul-16 11 11 LOFTAIR GLYCOPYRROLATE + INDACATEROL LUPIN Dec-15 11 7 EASY SIX ALL OTHER VACCINES PANACEA Apr-17 11 11 ENSURE PLUS OTHER NUTRIENTS ABBOTT* Oct-15 11 9 CEASTRA ITRACONAZOLE EMCURE* Sep-16 11 11 6325 Brands launched in last 24 months…
  • 14. Dataset : PharmaTrac MAT JUN 2017